Please login to the form below

Not currently logged in
Email:
Password:

Takeda wins UK approval for cancer drug

Takeda's bone cancer treatment Mepact has won the backing of the UK's National Institute for Health and Clinical Excellence

Takeda Pharmaceutical won the backing of the UK's National Institute for Health and Clinical Excellence (NICE) for its Mepact (mifamurtide) drug, for the treatment of high-grade resectable non-metastic osteosarcoma.

Mepact is approved for use with chemotherapy after surgery for bone cancers that have not spread. The approval is conditional on Takeda providing a price discount, which it has agreed to do, according to NICE.

The agency reversed a decision from 2010 in which it rejected the drug. The initial economic analysis may not have adequately captured the health-related quality of life from the drug, NICE said.

The terms of the discount have not been disclosed at Takeda's request.

Takeda acquired the rights to Mepact when it purchased IDM Pharma in May, 2009.

7th September 2011

From: Healthcare

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Networks in Health

Networks in Health is the unique global alliance of trusted online physician networks founded and operated by Doctors.net.uk....

Latest intelligence

BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....
Online Physician Communities
How can pharma develop a more customer-centric approach?
Business pressures and customer needs will force pharma to focus on multichannel marketing in the next few years...
Exploring MINT: Part 2 - Indonesia
In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...